 |
11 Diseases |  |
1 Trial |
|
1 Trial |  |
409 News |  |
| «123456» |
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice. (Pubmed Central) - Apr 1, 2022
The GKA showed an unsustained hypoglycaemic effect and promoted hepatic fat accumulation in db/db mice. Dynamic changes in the expression of hepatic genes involved in lipogenesis and gluconeogenesis could affect the unsustained hypoglycaemic effect of the GKA despite no changes in pancreatic beta-cell function and mass.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Review, Journal: Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 30, 2022
SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Total MD = -34.07 μmol/L, 95% CI [-37.00, -31.14]).
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Retrospective data, Review, Journal: Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. (Pubmed Central) - Mar 18, 2022
SGLT2i led to significant increases in hemoglobin and hematocrit levels when compared to placebo. In addition to their cardiovascular effect, SGLT2i also increases hemoglobin and hematocrit levels.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Biomarker, Retrospective data, Review: Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Mar 15, 2022
To find the best guide-level drugs, it is necessary to include more RCTs with these off-label drugs, so that patients and clinicians can make optimal decisions together. https://www.crd.york.ac.uk/prospero, identifier: CRD42021283129.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. (Pubmed Central) - Mar 12, 2022
Among 2555 mouse miRNA probes, miR-19b-3p was commonly differentially expressed with ipragliflozin treatment for 5 weeks in both the liver and serum but in different directions, with a decrease in the liver and increase in the serum. Therefore, ipragliflozin can improve NASH development likely through the antioxidative stress pathway and by regulating miR-19b-3p.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Biomarker, Journal: The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes. (Pubmed Central) - Mar 11, 2022
The HOMA-beta and insulinogenic indices were not changed, but the C-peptide index was significantly increased. Although the number of patients was small, these results suggested that SGLT2i treatment improved liver function, decreased hepatic insulin resistance, and increased hepatic insulin clearance, despite the small weight reduction.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Journal: Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/SIRT1 Pathway. (Pubmed Central) - Mar 9, 2022
SGLT2 inhibition by ipragliflozin showed beneficial metabolic effects in 129S6/Sv mice with HFD-induced obesity that mimics prediabetic conditions. Our data suggest that SGLT2 inhibitors, through their upregulation of energy expenditure, may have therapeutic potential in prediabetic obesity.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Journal: Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. (Pubmed Central) - Mar 5, 2022
Thus, ipragliflozin might be effective for the treatment and prevention of NASH in patients with diabetes, as well as improving glycemic control and obesity. Therefore, SGLT2is may represent a therapeutic choice for patients with diabetes with NAFLD, but further larger studies are required to confirm these effects.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal, Head-to-Head: The evaluation of noninferiority for renal composite outcomes between sodium-glucose cotransporter inhibitors in Japan. (Pubmed Central) - Feb 1, 2022
Therefore, SGLT2is may represent a therapeutic choice for patients with diabetes with NAFLD, but further larger studies are required to confirm these effects. Three SGLT2Is with no CVOT's evidence did not show noninferiority compared with other SGLT2Is with evidences.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice. (Pubmed Central) - Jan 29, 2022
Thus, in a hyperglycemic state, ipragliflozin exerts a potent antihyperglycemic effect and marked increases in urinary glucose excretion; however, in a non-hyperglycemic or hypoglycemic state, the hypoglycemic effect is weak. Ipragliflozin may therefore be a useful antidiabetic agent for normalizing daily blood glucose fluctuations in type 2 diabetes.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, P4 data, Journal: Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM). (Pubmed Central) - Jan 21, 2022
FLI reductions at 36 months were significant (p < 0.001) in subgroups with baseline FLI of ≥30 or ≥60. In conclusion, ipragliflozin improved liver function over 3 years in patients with impaired liver function, although ADRs occurred more frequently than in the normal liver function group.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice. (Pubmed Central) - Jan 21, 2022
Leptin was peripherally administered at 20 μg/day using an osmotic pump, and an SGLT2 inhibitor, ipragliflozin, was orally administered at 3 mg/kg/day...Notably, glucose metabolism in the co-treatment group improved to the same level as that in the healthy mice group. Thus, peripheral combination treatment with leptin and SGLT2 inhibitor improved glucose metabolism in IDDM mice without the use of insulin.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Review, Journal: Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. (Pubmed Central) - Jan 1, 2022
However, no cardiovascular outcome trials have been conducted to date. Real-world observational studies are still needed to accurately capture any possible rare or long-term adverse events.
- | Victoza (liraglutide) / Novo Nordisk, Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages. (Pubmed Central) - Dec 16, 2021
Our data suggest that liraglutide is more efficient at an earlier stage and ipragliflozin can be effective in both stages. In addition, their combined use is a potential option for treating advanced stage diabetes with fatty liver disease.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal: Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. (Pubmed Central) - Dec 1, 2021
There were no significant differences in percent time with glucose at <70 mg/dL (TBR: time below range), minimum plasma glucose and low blood glucose index (LBGI). Our results using isCGM in an actual clinical setting showed that 7-day use of SGLT2-I with intensive insulin therapy improved plasma glucose fluctuations and mean plasma glucose levels without inducing hypoglycemia in patients with T1DM.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal, Combination therapy: Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Sub-analysis of a prospective, randomized, controlled study (PRIME-V study). (Pubmed Central) - Oct 13, 2021
However, ipragliflozin combination increased the levels of TRACP-5b. A long-term study is required to further understand the effects of this TRACP-5b increase caused by ipragliflozin.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Retrospective data, Review, Journal: Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis. (Pubmed Central) - Oct 6, 2021
A long-term study is required to further understand the effects of this TRACP-5b increase caused by ipragliflozin. The presented meta-analysis provides class one evidence that ipragliflozin is safe and effective in the management of T2DM either as monotherapy or an add-on.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Journal, Real-world evidence: Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial. (Pubmed Central) - Sep 28, 2021
Ipragliflozin is useful and safe, showing some contrastive effects on several clinical parameters which are not shown with DPP-4i, resulting several clinical benefits. The co-administration of ipragliflozin and a DPP-4i has a better clinical outcome than either single-agent therapy.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, P4 data, Journal, HEOR, Real-world evidence: Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM). (Pubmed Central) - Sep 28, 2021
P=N/A
ClinicalTrials.gov: NCT02479399. The online version contains supplementary material available at 10.1007/s13340-021-00501-w.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Journal: SGLT2 inhibitors improved time in range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective single-center pilot study. (Pubmed Central) - Sep 16, 2021
The online version contains supplementary material available at 10.1007/s13340-021-00501-w. SGLT2 inhibitors improved TIR and the mean glucose level and standard deviation without increasing the time below range <70 mg/dL in patients with type 1 diabetes.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Journal: Effects of ipragliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the multicenter prospective intervention study. (Pubmed Central) - Sep 16, 2021
Ipragliflozin lowers eGFR and corrects hyperfiltration in patients with high eGFR (eGFR ≥60). In patients with low eGFR (eGFR ≥30 to <60), ipragliflozin has the possibility of increasing eGFR and exerting a renoprotective effect.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: SGLT2 inhibitor ipragliflozin poses a low risk of hypoglycemia owing to its blood glucose-dependent urinary glucose excretion mechanism in mice. (Pubmed Central) - Sep 9, 2021
These results suggest that ipragliflozin-induced increases in urinary glucose excretion and accompanying hypoglycemic effects were caused by blood glucose-dependent mechanisms. Thus, ipragliflozin may be a useful antidiabetic agent that achieves ideal blood glucose control in diabetic patients with little risk of hypoglycemia.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Efficacy and Safety of Ipragliflozin in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control on Sitagliptin. (Pubmed Central) - Aug 13, 2021
P3
Ipragliflozin 50 mg q.d. added on to sitagliptin 50 mg q.d. monotherapy provided significant improvement in glycemic control and was generally well tolerated in Japanese patients with T2D. CLINICAL TRIALS.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice. (Pubmed Central) - Aug 6, 2021
These findings suggest that Ipra-induced PRAT expansion may play an important role in the improvement of DN in HFD-fed mice. In vitro experiments suggest that reduced PRAT-derived leptin by Ipra could inhibit GECs proliferation, possibly contributing to the suppression of DN development.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome. (Pubmed Central) - Jul 28, 2021
We found that intragastric phlorizin did not display any effects, but ipragliflozin, an orally active and selective SGLT2 inhibitor improved the gastrointestinal changes in the LPS model...These effects may result from inhibition of SGLT2, and were mediated via AMPK, NO and opioid pathways. Phlorizin may be effective for the treatment of IBS.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Review, Journal: The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Jul 14, 2021
Phlorizin may be effective for the treatment of IBS. SGLT2 inhibitors, as a class of drugs, increased Hct levels in patients with type 2 diabetes, and this increase was slightly more pronounced at higher doses compared to lower doses.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: A Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Sitagliptin in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control on Ipragliflozin. (Pubmed Central) - Jul 11, 2021
P3
SGLT2 inhibitors, as a class of drugs, increased Hct levels in patients with type 2 diabetes, and this increase was slightly more pronounced at higher doses compared to lower doses. In Japanese patients with T2D, sitagliptin 50 mg q.d. added to ipragliflozin 50 mg q.d. monotherapy provided significant improvement in glycemic control and was generally well tolerated.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Observational data, Journal: Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. (Pubmed Central) - Jun 8, 2021
The 2016-2017 increased prescription volume also varied among prefectures by as large as 7.3-fold for ipragliflozin. Regression analysis revealed that the annual and increased prescription volume of all the SGLT2 inhibitors except luseogliflozin were higher in regions with more certified cardiologists (P < 0.05), even after adjusting for regional parameters.In conclusion, the regional number of certified cardiologists was positively associated with a 2016 annual of and 2016-2017 increase in SGLT2 inhibitor prescription amount, implying an early adopter role of clinical experts in healthcare delivery.
- Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
[VIRTUAL] Difference in Glycemic Control between Ipragliflozin (Ipr) and Sitagliptin (Sit) According to Changes in Energy Intake (EI) and Physical Activity (PA): Post-hoc Analysis of the NISM Study () - May 29, 2021 - Abstract #ADA2021ADA_1182;
Both SGLT2i and DPP4i improved HbA1c despite increasing EI, but glycemic control was attenuated with SGLT2i compared with DPP4i in those with increased EI. These results suggested the importance of avoiding increases in EI at least when taking SGLT2 inhibitors.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, PK/PD data, Journal: Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin between Patients with Type 1 and Type 2 Diabetes Mellitus. (Pubmed Central) - May 20, 2021
P1, P2
The dose regimen used for patients with T2DM was also recommended for a Phase III study in Japanese patients with T1DM. ClinicalTrials.gov identifiers: NCT01023945 and NCT02529449.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, P4 data, Journal, HEOR, Real-world evidence: Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM). (Pubmed Central) - Apr 28, 2021
The safety profile of long-term ipragliflozin treatment in routine clinical practice is consistent with previously reported interim data at 12 or 24 months and pre-approval clinical trials. Ipragliflozin treatment was also associated with sustained improvements in efficacy parameters for over 3 years.
- ||| Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Trial completion date, Trial primary completion date: Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin (clinicaltrials.gov) - Apr 22, 2021
P3, N=170, Recruiting, Sponsor: Seoul National University Bundang Hospital
Ipragliflozin treatment was also associated with sustained improvements in efficacy parameters for over 3 years. Trial completion date: Dec 2020 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. (Pubmed Central) - Apr 7, 2021
Combination treatment with ipragliflozin+pioglitazone attenuated these symptoms by ipragliflozin-induced osmotic diuresis. These findings demonstrate that treatment with ipragliflozin monotherapy or coadministered with pioglitazone may be a potential therapeutic option for the treatment of type 2 diabetes with NASH without fluid retention as a side effect.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, P4 data, Journal: Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM). (Pubmed Central) - Apr 1, 2021
It decreased in the ≥ 90 and 60 to < 90 mL/min/1.73 m subgroups (- 8.27 ± 13.73 and - 1.22 ± 10.34 mL/min/1.73 m; P < 0.001), but not to < 60 mL/min/1.73 m. In conclusion, there were no new or unexpected safety findings in Japanese patients treated with ipragliflozin for T2DM, and long-term sustained improvements in HbA1c and bodyweight were observed regardless of the presence of renal impairment.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Journal: Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. (Pubmed Central) - Apr 1, 2021
Trial registration: This trial has been registered with University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR no. 000015478).
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
Journal: Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus. (Pubmed Central) - Mar 26, 2021
000015478). Although semaglutide, dapaglifrozin, and canagliflozin have a large weight loss effect, it is important to pay attention to muscle loss because a decrease in FFM was observed.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
[VIRTUAL] Efficacy of Semaglutide by Background Sodium – Glucose Co-Transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9 (Channel 4) - Mar 21, 2021 - Abstract #DDG2021DDG_469;
SUSTAIN 9 investigated semaglutide 1.0 mg vs placebo as add-on to a stable dose of sodium-glucose co transporter-2 inhibitor (SGLT-2i) therapy, with or without metformin or a sulfonylurea...In this post hoc analysis, SUSTAIN 9 data were analyzed by background SGLT-2i (empagliflozin, canagliflozin, dapagliflozin or other [ipragliflozin, luseogliflozin and tofogliflozin; drugs available only in Japan])...In conclusion, in subjects with T2D already receiving an SGLT-2i, semaglutide generally resulted in superior HbA1c and body weight reductions vs placebo, regardless of background SGLT-2i therapy. Joachim Kienhöfer is just presenting on behalf of the author group (Sponsored by Novo Nordisk A / S).
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Journal: Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial. (Pubmed Central) - Mar 20, 2021
SGLT2 inhibitors have beneficial effects on glycemic variabilities and fat mass reductions in patients with type 1 diabetes mellitus. However, loss of skeletal muscle is a major concern; therefore, caution is required when using SGLT2 inhibitors in lean patients with type 1 diabetes mellitus.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Journal: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM. (Pubmed Central) - Mar 18, 2021
P=N/A
Ipragliflozin was well tolerated and effective for 3 years in routine clinical use in elderly and non-elderly patients, although elderly patients had a higher rate of serious ADRs. No new safety concerns were identified.
- Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Ocaliva (obeticholic acid) / Intercept
[VIRTUAL] COMPARATIVE NETWORK META-ANALYSIS FOR EFFICACY OF PHARMACOLOGICAL MODALITIES FOR NON-ALCOHOLIC FATTY LIVER DISEASE(NAFLD) (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_2924;
No new safety concerns were identified. Liraglutide, vitamin E, metformin, and obeticholic acid showed significant improvement of liver function that render them attractive therapies for patients with nonalcoholic steatohepatitis.
- ||| Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, P3 data, Journal: Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase 3 study. (Pubmed Central) - Feb 18, 2021
The efficacy and safety of 50 mg, once-daily ipragliflozin in insulin-treated type 1 diabetes mellitus patients were confirmed in this long-term, open-label extension study. No safety concerns were attributed to a dose increase to 100 mg.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal: Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes (Pubmed Central) - Feb 12, 2021
Administration of ipragliflozin at 50 mg improved the hyperglycemia mainly at night (mean blood glucose, before administration: 205 mg/dl, day 6 of treatment: 119 mg/dl)...She was morbidly obese and presented with poor glycemic control (HbA1c: 9-11%) although she was being treated with more than 50 units/day of insulin and 2,250 mg of metformin...Administration of dapagliflozin at 5 mg improved the hyperglycemia mainly at night on day 2 with improvement in the mean blood glucose level from 188 mg/dl before administration to 128 mg/dl on day 5...These agents also have various other effects, including weight loss, improvement of blood pressure and lipid metabolism. Here we report the short-term glucose lowering effects of two SGLT2 inhibitors, as confirmed by FGM, in two outpatients with type 1 diabetes.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal: Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. (Pubmed Central) - Jan 21, 2021
SGLT2 inhibitors also reduce liver fat in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. This chapter describes the basic information about SGLT2 inhibitors, current status of SGLT2 inhibitors in the management of type 2 diabetes and their beneficial effects in addition to glycemic control.
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Retrospective data, Review, Journal: Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jan 6, 2021
Compared to placebo/reference therapy, treatment with SGLT-2 inhibitors significantly decreased serum alanine aminotransferase (weighted mean differences (WMD): -10.0 IU/L, 95%CI -12.2 to -7.79 IU/L; I = 10.5%) and gamma-glutamyltransferase levels (WMD: -14.49 IU/L, 95%CI -19.35 to -9.63 IU/L, I = 38.7%), as well as the absolute percentage of liver fat content on magnetic resonance-based techniques (WMD: -2.05%, 95%CI -2.61 to -1.48%; I = 0%). In conclusion, SGLT-2 inhibitors seem to be a promising treatment option for NAFLD.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Journal: Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy. (Pubmed Central) - Dec 22, 2020
In conclusion, SGLT-2 inhibitors seem to be a promising treatment option for NAFLD. The present study provides a novel crosstalk mechanism between SGLT2 inhibition and megalin underlying the potential renal benefits of SGLT2 inhibition in DN.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Journal: Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus. (Pubmed Central) - Dec 17, 2020
Ipragliflozin has acute natriuretic activity, and first-morning urine sodium and baseline dosage of loop diuretics strongly predicted the diuretic effects. Ipragliflozin therapy may restore responsiveness to loop diuretics in symptomatic HF patients with T2DM.
- || Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Clinical, Journal: Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan. (Pubmed Central) - Nov 27, 2020
Ipragliflozin therapy may restore responsiveness to loop diuretics in symptomatic HF patients with T2DM. SGLT2 inhibitors may improve clinical treatment satisfaction by improving glycemic variability in patients with type 1 diabetes mellitus, while not inducing severe side effects with careful use.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Preclinical, Journal: Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. (Pubmed Central) - Nov 27, 2020
In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms. These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas, Byetta (exenatide) / AstraZeneca
Journal: SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. (Pubmed Central) - Nov 21, 2020
Furthermore, JC-1 green fluorescence was significantly increased by ipragliflozin, suggesting the change of mitochondrial membrane potential. These findings suggest that the SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation via membrane hyperpolarization and mitochondrial membrane instability.
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Journal: Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. (Pubmed Central) - Nov 12, 2020
In conclusion, the SGLT2 inhibitor ipragliflozin induced a sustained glucosuria, diuresis, and natriuresis, with compensatory increases in fluid intake and vasopressin-induced TcH2O in proportion to the reduced fluid balance to maintain BFV. These results indicate that the osmotic diuresis induced by SGLT2 inhibition stimulates compensatory fluid intake and renal water reabsorption to maintain BFV.